The potential of PAR-2 antagonist for treatment of IPF-acute exacarbation

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461192
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Fukushima Medical University
• Principal Investigator: Suzuki Tomoko 福島県立医科大学, 公私立大学の部局等, 准教授 (10400342)
• Co-Investigator(Kenkyū-buntansha): 棟方 充 福島県立医科大学, 医学部, 教授 (00209991) ; 谷野 功典 福島県立医科大学, 医学部, 准教授 (10443863) ; 王 新涛 福島県立医科大学, 医学部, 助教 (00448630)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 肺線維症急性増悪

Outline of Final Research Achievements

To investigate a potential of PAR-2 antagonist for treatment of idiopathic pulmonary fibrosis-acute exacerbation, we studied anti-inflammation and anti-fibrotic effects for bleomycin-treated mice.
The number of lymphocytes in bronchoalveolar lavage fluid (BALF) of BLM mice treated intranasally with PAR-2 inhibiting peptide (IP) was significantly reduced, and infiltrations of inflammatory cells in lung were also suppressed. Total collagen in lungs of PAR-2IP-treated BLM mice was significantly reduced. Furthermore, Yimentin on PAR-2IP-treated BLM mice was less expressed than in BLM mice. Therefore, PAR-2 IP has anti-inflammatory effect, and inhibits BLM-induced fibrosis through the control of epithelial-mesenchymal transition.

Free Research Field

呼吸器内科